Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis

Volume: Volume 12, Pages: 3879 - 3883
Published: Nov 1, 2018
Abstract
Risankizumab, a fully human IgG monoclonal antibody inhibitor of IL-23, is a therapeutic agent currently in late stage development for use in the treatment of moderate-to-severe plaque psoriasis. It is a biologic agent similar to guselkumab and tildrakizumab which targets IL-23 specifically, and has been primarily developed for use in moderate-to-severe psoriasis. USA-based pharmaceutical company Abbvie submitted it for a Biologics License...
Paper Details
Title
Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis
Published Date
Nov 1, 2018
Volume
Volume 12
Pages
3879 - 3883
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.